NEUP
NASDAQ · Biotechnology
Neuphoria Therapeutics Inc
$4.88
-0.21 (-4.13%)
Financial Highlights (FY 2026)
Revenue
54.22M
Net Income
-1,282,016
Gross Margin
—
Profit Margin
-2.4%
Rev Growth
+696.2%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 66.4% | 66.4% | 66.4% |
| Operating Margin | -7.2% | -5.9% | -6.8% | -6.3% |
| Profit Margin | -2.4% | -6.9% | -5.3% | -5.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 54.22M | 5.17M | 4.87M | 5.69M |
| Gross Profit | — | 3.43M | 3.24M | 3.78M |
| Operating Income | -3,908,959 | -305,443 | -332,181 | -355,674 |
| Net Income | -1,282,016 | -354,866 | -256,361 | -296,488 |
| Gross Margin | — | 66.4% | 66.4% | 66.4% |
| Operating Margin | -7.2% | -5.9% | -6.8% | -6.3% |
| Profit Margin | -2.4% | -6.9% | -5.3% | -5.2% |
| Rev Growth | +696.2% | -7.1% | +6.1% | +23.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 23.3K | 5.39M | 4.38M | 5.69M |
| Total Equity | 13.70M | 13.97M | 15.22M | 15.00M |
| D/E Ratio | 0.00 | 0.39 | 0.29 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 255.8K | -507,265 | -425,609 | -470,962 |
| Free Cash Flow | — | -183,163 | -132,058 | -138,324 |